The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.
The user is generally happy with their hair transplant results but has concerns about graft density and placement, particularly on the left temple and hairline. They are using finasteride and minoxidil inconsistently, plan to add Priorin, and are considering microneedling and PRP sessions for future care.
A 21-year-old MTF individual is experiencing rapid hair thinning and is currently on estradiol valerate. They are inquiring about the effectiveness of spironolactone for hair loss, despite being aware of its serious side effects.
User shared 9-month hair regrowth progress using a Fin/Min spray from HIMS, with additional microneedling. Other users praised the results and discussed the effectiveness of topical treatments.
The conversation is about a user experiencing hair shedding after using a brand of RU58841, questioning its effectiveness and safety. Concerns are raised about RU58841 being an abandoned research chemical and the use of heavy oils like castor and argan oil potentially affecting absorption.
PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.
The user is experiencing scalp irritation after increasing their finasteride and minoxidil dosage with tretinoin and is considering reducing application frequency. They seek advice on managing the irritation.
There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.
The conversation discusses the effects of finasteride on hair loss and its potential neurological and sexual side effects. Users share personal experiences, with some reporting positive outcomes and others expressing concerns about cognitive function.
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.